Workflow
盈利预期调整
icon
搜索文档
TriNet Group (TNET) Q3 Earnings and Revenues Beat Estimates
ZACKS· 2025-10-29 21:20
TriNet Group (TNET) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +54.17%. A quarter ago, it was expected that this human resources services outsourcing company would post earnings of $1 per share when it actually produced earnings of $1.15, delivering a surprise of +15%.Over the la ...
American Electric Power (AEP) Lags Q3 Earnings Estimates
ZACKS· 2025-10-29 21:05
公司最新季度业绩 - 最新季度每股收益为1.8美元,低于市场预期的1.81美元,同比去年的1.85美元有所下降,经调整后每股收益意外为-0.55% [1] - 上一季度每股收益为1.43美元,远超预期的1.28美元,收益意外达到+11.72% [1] - 过去四个季度中,公司有两次每股收益超出市场预期 [2] 公司营收表现 - 最新季度营收为60.1亿美元,远超市场预期6.46%,同比去年同期的54亿美元有所增长 [2] - 过去四个季度中,公司有三次营收超出市场预期 [2] 公司股价表现与市场展望 - 公司股价年初至今上涨约24.8%,表现优于同期标普500指数17.2%的涨幅 [3] - 公司当前的Zacks评级为第3级(持有),预计近期表现将与市场同步 [6] - 对公司未来业绩的预估修订趋势好坏参半,当前市场对下一季度的每股收益预期为1.13美元,营收预期为51.1亿美元 [7] 行业状况与同业比较 - 公司所属的电力公用事业行业在Zacks行业排名中位列前21% [8] - 同业公司AES预计将于11月4日公布季度业绩,预计每股收益为0.78美元,同比增长9.9% [9] - 过去30天内,市场对AES的每股收益预期下调了18.5%,其季度营收预计为33.1亿美元,同比增长0.7% [9][10]
GE HealthCare Technologies (GEHC) Surpasses Q3 Earnings and Revenue Estimates
ZACKS· 2025-10-29 20:31
GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.07 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.90%. A quarter ago, it was expected that this medical technology company would post earnings of $0.91 per share when it actually produced earnings of $1.06, delivering a surprise of +16.48%.Over the l ...
Otis Worldwide (OTIS) Beats Q3 Earnings and Revenue Estimates
ZACKS· 2025-10-29 20:16
Otis Worldwide (OTIS) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.96 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.00%. A quarter ago, it was expected that this company would post earnings of $1.02 per share when it actually produced earnings of $1.05, delivering a surprise of +2.94%.Over the last four quarters, the company has ...
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
ZACKS· 2025-10-29 20:06
核心业绩表现 - 季度每股收益为1.48美元 超出市场预期的1.26美元 相比去年同期的1.27美元有所增长 [1] - 本季度收益超出预期17.46% 上一季度收益为1.23美元 超出预期9.82% [1] - 季度营收为115.2亿美元 超出市场预期3.23% 相比去年同期的104.2亿美元有所增长 [2] - 公司在过去四个季度中四次超出每股收益预期 三次超出营收预期 [2] 股价表现与市场比较 - 公司股价自年初以来上涨约29.2% 同期标普500指数上涨17.2% [3] - 公司股票目前的Zacks评级为3级(持有) 预计近期表现将与市场同步 [6] 未来业绩预期 - 市场对下一季度的共识预期为每股收益0.68美元 营收110.1亿美元 [7] - 对本财年的共识预期为每股收益4.37美元 营收425.6亿美元 [7] 行业背景与同业比较 - 公司所属的医疗-生物医学和遗传学行业在Zacks行业排名中处于前37%分位 [8] - 同业公司Janux Therapeutics预计将公布季度每股亏损0.60美元 同比变化-17.7% [9] - Janux Therapeutics预计季度营收为781万美元 较去年同期增长1675.5% [9]
First Busey (BUSE) Q3 Earnings and Revenues Beat Estimates
ZACKS· 2025-10-29 07:11
First Busey (BUSE) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.23%. A quarter ago, it was expected that this bank holding company would post earnings of $0.61 per share when it actually produced earnings of $0.63, delivering a surprise of +3.28%.Over the last four quarters, the ...
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates
ZACKS· 2025-10-29 06:56
季度业绩表现 - 季度每股亏损为127美元 优于市场预期的每股亏损133美元 形成451%的盈利惊喜 [1] - 季度营收为2600万美元 超出市场预期2720% 但较去年同期的4800万美元有所下降 [2] - 在过去四个季度中 公司有三次每股收益和三次营收超出市场预期 [2] 历史业绩与市场表现 - 上一季度业绩表现强劲 实际实现盈亏平衡 而市场预期为每股亏损114美元 盈利惊喜达到100% [1] - 公司股价自年初以来上涨约249% 表现优于同期标普500指数169%的涨幅 [3] 未来业绩预期与行业比较 - 当前市场对下一季度的共识预期为每股亏损124美元 营收2006万美元 对本财年的共识预期为每股亏损370美元 营收22848亿美元 [7] - 公司所属的医疗生物医学和遗传学行业在Zacks行业排名中位列前37% 该排名前50%行业的表现通常优于后50%行业两倍以上 [8] - 同业公司TG Therapeutics预计季度每股收益为024美元 同比增长1100% 预计营收为15066亿美元 同比增长796% [9] 近期展望与评级 - 公司目前的Zacks评级为3级(持有) 预计近期股价表现将与市场同步 [6] - 业绩发布前的预期修订趋势好坏参半 未来的预期变化值得关注 [6]
Renasant (RNST) Misses Q3 Earnings Estimates
ZACKS· 2025-10-29 06:46
核心业绩表现 - 2025年第三季度每股收益为0.77美元,低于市场预期的0.79美元,但高于去年同期的0.70美元,构成-2.53%的业绩意外 [1] - 当季总收入为2.6955亿美元,超出市场预期1.30%,且高于去年同期的2.203亿美元 [2] - 在过去四个季度中,公司有两次每股收益超出预期,但四次收入均超出预期 [2] 近期股价与市场表现 - 公司股价自年初以来下跌约2.2%,而同期标普500指数上涨16.9% [3] - 公司股票当前的Zacks评级为3级(持有),预计短期内表现将与市场同步 [6] 未来业绩展望 - 市场对下一季度的共识预期为每股收益0.80美元,收入2.6597亿美元 [7] - 对本财年的共识预期为每股收益2.98美元,收入9.6987亿美元 [7] - 业绩公布前,市场对公司的盈利预期修正趋势好坏参半 [6] 行业比较与前景 - 公司所属的东南地区银行业在250多个Zacks行业中排名前26% [8] - 同行业公司First National Corp (FXNC) 预计将公布季度每股收益0.58美元,同比增长48.7%,预计收入2240万美元,同比增长49.8% [9]
Aurora Innovation, Inc. (AUR) Reports Q3 Loss, Lags Revenue Estimates
ZACKS· 2025-10-29 06:40
财务业绩 - 公司本季度每股亏损0.11美元 优于市场预期的每股亏损0.12美元 与去年同期每股亏损0.13美元相比有所收窄 [1] - 本季度盈利超出预期8.33% 上一季度同样超出预期8.33% 在过去四个季度中 公司两次超出每股收益预期 [1][2] - 公司本季度营收为100万美元 较去年同期为零营收有所增长 但低于市场预期21.88% [2] 市场表现与预期 - 公司股价年初至今下跌约16.4% 同期标普500指数上涨16.9% [3] - 公司目前的Zacks评级为2级(买入) 预计短期内将跑赢市场 [6] - 对下一季度的市场共识预期为每股亏损0.13美元 营收254万美元 对本财年的共识预期为每股亏损0.48美元 营收450万美元 [7] 行业比较 - 公司所属的技术服务行业在Zacks行业排名中位列前32% 研究表明排名前50%的行业表现优于后50%的行业超过两倍 [8] - 同业公司Veritone Inc (VERI) 预计在即将发布的报告中公布季度每股亏损0.11美元 同比改善42.1% 预计营收为2860万美元 同比增长30.1% [9]
Nabors Industries (NBR) Reports Q3 Loss, Misses Revenue Estimates
ZACKS· 2025-10-29 06:36
Nabors Industries (NBR) came out with a quarterly loss of $3.67 per share versus the Zacks Consensus Estimate of a loss of $2.37. This compares to a loss of $3.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -54.85%. A quarter ago, it was expected that this drilling contractor would post a loss of $2.05 per share when it actually produced a loss of $2.71, delivering a surprise of -32.2%.Over the last four quarters, the comp ...